Abstract
Photodynamic therapy (PDT) using hematoporphyrin derviative (HpD), and its more purified form dihematoporphyrin ether (DHE), in combination with dye-laser systems is undergoing a great deal of study for the treatment of a variety of cancers. Results to date are promising in a number of tumor types and organs. The mode of delivery of the activating light and the dosimetry of light delivered and therapeutic reaction obtained are extremely important in obtaining significant and selective tumor response. The optimum wavelength for activation of HpD or DHE in vivo is 630 + 2 nm, which is usually obtained from a continuous argon-pumped dye laser. Delivery to the patient is via single optical fibers. A variety of distal tips have been developed for the fibers to permit optimum delivery of the light in a variety of geometries. Systems include cylindrical and point-source diffusers and microlens systems. The operational parameters of the systems have been characterized and documented.
© 1984 Optical Society of America
PDF ArticleMore Like This
Daniel R. Doiron, Charles J. Gomer, Stanley W. Fountain, Nicholas J. Razum, and A. Linn Murphree
FG1 Conference on Lasers and Electro-Optics (CLEO:S&I) 1984
Thomas J. Dougherty
FB1 Conference on Lasers and Electro-Optics (CLEO:S&I) 1984
Thomas J. Dougherty
FB1 International Quantum Electronics Conference (IQEC) 1984